JP2025003992A5 - - Google Patents
Info
- Publication number
- JP2025003992A5 JP2025003992A5 JP2024158942A JP2024158942A JP2025003992A5 JP 2025003992 A5 JP2025003992 A5 JP 2025003992A5 JP 2024158942 A JP2024158942 A JP 2024158942A JP 2024158942 A JP2024158942 A JP 2024158942A JP 2025003992 A5 JP2025003992 A5 JP 2025003992A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide
- oligonucleotide
- ribonucleotide
- methoxyethyl
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962795357P | 2019-01-22 | 2019-01-22 | |
| US62/795,357 | 2019-01-22 | ||
| US201962822472P | 2019-03-22 | 2019-03-22 | |
| US62/822,472 | 2019-03-22 | ||
| US201962900019P | 2019-09-13 | 2019-09-13 | |
| US62/900,019 | 2019-09-13 | ||
| JP2021541718A JP7629404B2 (ja) | 2019-01-22 | 2020-01-22 | Rna編集オリゴヌクレオチド及びその使用 |
| PCT/US2020/014510 WO2020154342A1 (en) | 2019-01-22 | 2020-01-22 | Rna-editing oligonucleotides and uses thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021541718A Division JP7629404B2 (ja) | 2019-01-22 | 2020-01-22 | Rna編集オリゴヌクレオチド及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025003992A JP2025003992A (ja) | 2025-01-14 |
| JP2025003992A5 true JP2025003992A5 (cg-RX-API-DMAC10.html) | 2025-10-09 |
Family
ID=71736317
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021541718A Active JP7629404B2 (ja) | 2019-01-22 | 2020-01-22 | Rna編集オリゴヌクレオチド及びその使用 |
| JP2024158942A Pending JP2025003992A (ja) | 2019-01-22 | 2024-09-13 | Rna編集オリゴヌクレオチド及びその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021541718A Active JP7629404B2 (ja) | 2019-01-22 | 2020-01-22 | Rna編集オリゴヌクレオチド及びその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20200385713A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3914259A4 (cg-RX-API-DMAC10.html) |
| JP (2) | JP7629404B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20210132022A (cg-RX-API-DMAC10.html) |
| CN (1) | CN113453694A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2020210900B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3126947A1 (cg-RX-API-DMAC10.html) |
| TW (1) | TW202043469A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2020154342A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015367378A1 (en) | 2014-12-17 | 2017-06-15 | Proqr Therapeutics Ii B.V. | Targeted RNA editing |
| EP3475424A1 (en) | 2016-06-22 | 2019-05-01 | ProQR Therapeutics II B.V. | Single-stranded rna-editing oligonucleotides |
| WO2018041973A1 (en) | 2016-09-01 | 2018-03-08 | Proqr Therapeutics Ii B.V. | Chemically modified single-stranded rna-editing oligonucleotides |
| CN110612353A (zh) | 2017-03-03 | 2019-12-24 | 加利福尼亚大学董事会 | 经由抑制性tRNAs和脱氨酶对突变进行RNA靶向 |
| GB201808146D0 (en) | 2018-05-18 | 2018-07-11 | Proqr Therapeutics Ii Bv | Stereospecific Linkages in RNA Editing Oligonucleotides |
| AU2020210900B2 (en) | 2019-01-22 | 2025-04-24 | Korro Bio, Inc. | RNA-editing oligonucleotides and uses thereof |
| CN113573717A (zh) | 2019-01-22 | 2021-10-29 | 科罗生物公司 | Rna编辑的寡核苷酸及其用途 |
| CA3127241A1 (en) | 2019-01-22 | 2020-07-30 | Korro Bio, Inc. | Rna-editing oligonucleotides and uses thereof |
| GB201904709D0 (en) * | 2019-04-03 | 2019-05-15 | Proqr Therapeutics Ii Bv | Chemically modified oligonucleotides |
| WO2020252376A1 (en) * | 2019-06-13 | 2020-12-17 | Proqr Therapeutics Ii B.V. | Antisense rna editing oligonucleotides comprising cytidine analogs |
| US11827880B2 (en) | 2019-12-02 | 2023-11-28 | Shape Therapeutics Inc. | Therapeutic editing |
| EP4150087A1 (en) * | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2) |
| WO2021231691A1 (en) * | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi) |
| EP4150088A1 (en) * | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1) |
| JP2023529316A (ja) * | 2020-05-26 | 2023-07-10 | シェイプ セラピューティクス インコーポレイテッド | ゲノム編集のための組成物及び方法 |
| US20230194709A9 (en) * | 2021-06-29 | 2023-06-22 | Seagate Technology Llc | Range information detection using coherent pulse sets with selected waveform characteristics |
| CN118019848A (zh) * | 2021-09-29 | 2024-05-10 | 豪夫迈·罗氏有限公司 | Rna编辑 |
| KR20240103025A9 (ko) | 2021-11-16 | 2025-12-10 | 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. | 안지오텐시노겐(agt) 단백질의 발현을 저해하는 조성물 및 방법 |
| EP4479535A1 (en) | 2022-02-14 | 2024-12-25 | ProQR Therapeutics II B.V. | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia |
| CN115304656B (zh) * | 2022-06-22 | 2025-01-17 | 中国人民解放军海军军医大学第一附属医院 | 一种特异性激活细胞泛凋亡途径的囊泡药物构建及应用 |
| EP4555085A1 (en) | 2022-07-15 | 2025-05-21 | ProQR Therapeutics II B.V. | Chemically modified oligonucleotides for adar-mediated rna editing |
| EP4555086A1 (en) | 2022-07-15 | 2025-05-21 | ProQR Therapeutics II B.V. | Oligonucleotides for adar-mediated rna editing and use thereof |
| GB202215614D0 (en) | 2022-10-21 | 2022-12-07 | Proqr Therapeutics Ii Bv | Heteroduplex rna editing oligonucleotide complexes |
| KR20250113455A (ko) | 2022-11-24 | 2025-07-25 | 프로큐알 테라퓨틱스 Ⅱ 비.브이. | 유전성 hfe-혈색소침착증의 치료를 위한 안티센스 올리고뉴클레오티드 |
| GB202218090D0 (en) | 2022-12-01 | 2023-01-18 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency |
| WO2024121373A1 (en) | 2022-12-09 | 2024-06-13 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of cardiovascular disease |
| US20240293555A1 (en) * | 2022-12-12 | 2024-09-05 | University Of Massachusetts | Carbohydrate conjugates for the delivery of therapeutic oligonucleotides |
| GB202300865D0 (en) | 2023-01-20 | 2023-03-08 | Proqr Therapeutics Ii Bv | Delivery of oligonucleotides |
| WO2024175550A1 (en) | 2023-02-20 | 2024-08-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease |
| JP2026510408A (ja) | 2023-03-24 | 2026-04-02 | プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ | 神経障害の処置のためのアンチセンスオリゴヌクレオチド |
| GB202304363D0 (en) | 2023-03-24 | 2023-05-10 | Proqr Therapeutics Ii Bv | Chemically modified antisense oligonucleotides for use in RNA editing |
| EP4688143A1 (en) | 2023-03-27 | 2026-02-11 | ProQR Therapeutics II B.V. | Antisense oligonucleotides for the treatment of liver disease |
| WO2024220934A1 (en) | 2023-04-21 | 2024-10-24 | University Of Rochester | Nucleic acid molecules for pseudouridylation |
| WO2024256620A1 (en) | 2023-06-16 | 2024-12-19 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurodegenerative disease |
| AU2024287308A1 (en) * | 2023-07-13 | 2025-12-18 | Korro Bio, Inc. | Rna-editing oligonucleotides and uses thereof |
| EP4774393A1 (en) | 2023-09-07 | 2026-07-15 | ProQR Therapeutics II B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
| WO2025096809A1 (en) | 2023-10-31 | 2025-05-08 | Korro Bio, Inc. | Oligonucleotides comprising phosphoramidate internucleotide linkages |
| AU2024379264A1 (en) | 2023-11-16 | 2026-05-14 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of classic galactosemia |
| AU2024402199A1 (en) | 2023-12-20 | 2026-07-16 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of huntington's disease |
| GB202404661D0 (en) | 2024-04-02 | 2024-05-15 | Proqr Therapeutics Ii Bv | Antisense oligoncleotides for the treatment of liver disease |
| GB202405143D0 (en) | 2024-04-11 | 2024-05-29 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of poly-q disease |
| WO2025224230A1 (en) | 2024-04-25 | 2025-10-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of fatty liver disease |
| GB202410081D0 (en) | 2024-07-11 | 2024-08-28 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of cardiovascular disease |
| WO2026022136A1 (en) | 2024-07-23 | 2026-01-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
| WO2026050243A1 (en) | 2024-08-26 | 2026-03-05 | Korro Bio, Inc. | Galnac conjugated oligonucleotides for rna editing |
| WO2026060374A2 (en) | 2024-09-16 | 2026-03-19 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurological disorders |
| WO2026068781A1 (en) | 2024-09-30 | 2026-04-02 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of liver disease |
| WO2026080897A1 (en) | 2024-10-11 | 2026-04-16 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of chronic pain |
| WO2026093339A1 (en) | 2024-10-29 | 2026-05-07 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of peroxisome biogenesis disorders in the zellweger spectrum (pbd-zsd) |
| WO2026122478A1 (en) | 2024-12-02 | 2026-06-11 | Korro Bio, Inc. | Extrahepatic delivery formulations and methods |
| WO2026136379A1 (en) | 2024-12-17 | 2026-06-25 | Korro Bio, Inc. | Rna-editing oligonucleotides and uses thereof |
| WO2026136663A1 (en) | 2024-12-18 | 2026-06-25 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurodegenerative disease |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5399676A (en) | 1989-10-23 | 1995-03-21 | Gilead Sciences | Oligonucleotides with inverted polarity |
| US5314893A (en) | 1993-01-25 | 1994-05-24 | Bristol-Myers Squibb Co. | Antiviral tetrahydropyrans |
| CA2326823A1 (en) | 1998-04-20 | 1999-10-28 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid molecules with novel chemical compositions capable of modulating gene expression |
| ATE346918T1 (de) * | 1998-06-19 | 2006-12-15 | Univ Mcgill | Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide |
| CA2419563C (en) * | 2000-09-06 | 2018-03-20 | Mcgill University | Chimeric antisense of arabinofuranose analogue and deoxyribose nucleotides |
| US6878805B2 (en) | 2002-08-16 | 2005-04-12 | Isis Pharmaceuticals, Inc. | Peptide-conjugated oligomeric compounds |
| US8192937B2 (en) | 2004-04-07 | 2012-06-05 | Exiqon A/S | Methods for quantification of microRNAs and small interfering RNAs |
| US20110065774A1 (en) | 2008-01-31 | 2011-03-17 | Alnylam Pharmaceuticals | Chemically modified oligonucleotides and uses thereof |
| TWI595885B (zh) | 2012-05-02 | 2017-08-21 | 喜納製藥公司 | 包含四galnac之新穎結合物及傳送寡核苷酸之方法 |
| US9650627B1 (en) | 2012-07-19 | 2017-05-16 | University Of Puerto Rico | Site-directed RNA editing |
| US9943604B2 (en) * | 2013-09-20 | 2018-04-17 | Ionis Pharmaceuticals, Inc. | Targeted therapeutic nucleosides and their use |
| WO2015168589A2 (en) | 2014-05-01 | 2015-11-05 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating angiopoietin-like 3 expression |
| DE102014007158A1 (de) | 2014-05-16 | 2015-11-19 | Ugichem Gmbh | Neue Peptid-Nukleinsäuren-Monomere und -Oligomere |
| CN107532162A (zh) | 2014-12-12 | 2018-01-02 | 托德·M·伍尔夫 | 用于利用寡核苷酸编辑细胞中核酸的组合物和方法 |
| AU2015367378A1 (en) | 2014-12-17 | 2017-06-15 | Proqr Therapeutics Ii B.V. | Targeted RNA editing |
| WO2017010556A1 (ja) | 2015-07-14 | 2017-01-19 | 学校法人福岡大学 | 部位特異的rna変異導入方法およびそれに使用する標的編集ガイドrnaならびに標的rna-標的編集ガイドrna複合体 |
| DE102015012522B3 (de) | 2015-09-26 | 2016-06-02 | Eberhard Karls Universität Tübingen | Verfahren und Substanzen zur gerichteten RNA-Editierung |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| WO2017146186A1 (ja) * | 2016-02-26 | 2017-08-31 | 塩野義製薬株式会社 | Ampk活性化作用を有する5-フェニルアザインドール誘導体 |
| JP7069135B2 (ja) | 2016-06-15 | 2022-05-17 | ユニヴァーシティー オブ ユタ リサーチ ファウンデーション | アルブミンベースのナノ医薬品を使用するための組成物及び方法 |
| EP3475424A1 (en) * | 2016-06-22 | 2019-05-01 | ProQR Therapeutics II B.V. | Single-stranded rna-editing oligonucleotides |
| WO2018027078A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
| WO2018041973A1 (en) * | 2016-09-01 | 2018-03-08 | Proqr Therapeutics Ii B.V. | Chemically modified single-stranded rna-editing oligonucleotides |
| US11274300B2 (en) | 2017-01-19 | 2022-03-15 | Proqr Therapeutics Ii B.V. | Oligonucleotide complexes for use in RNA editing |
| CN110959039B (zh) * | 2017-03-15 | 2025-03-14 | 博德研究所 | 新型cas13b直向同源物crispr酶和系统 |
| AU2018251801B2 (en) * | 2017-04-12 | 2024-11-07 | Massachusetts Institute Of Technology | Novel type VI CRISPR orthologs and systems |
| KR102678809B1 (ko) * | 2017-05-18 | 2024-06-26 | 더 브로드 인스티튜트, 인코퍼레이티드 | 표적화된 핵산 편집을 위한 시스템, 방법 및 조성물 |
| KR102338449B1 (ko) | 2017-09-21 | 2021-12-10 | 더 브로드 인스티튜트, 인코퍼레이티드 | 표적화된 핵산 편집을 위한 시스템, 방법, 및 조성물 |
| WO2019111957A1 (ja) | 2017-12-06 | 2019-06-13 | 学校法人福岡大学 | オリゴヌクレオチド、その製造方法及び標的rnaの部位特異的編集方法 |
| WO2019152416A1 (en) | 2018-01-30 | 2019-08-08 | Metro International Biotech, Llc | Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof |
| EP3752611A1 (en) | 2018-02-14 | 2020-12-23 | ProQR Therapeutics II B.V. | Antisense oligonucleotides for rna editing |
| GB201808146D0 (en) | 2018-05-18 | 2018-07-11 | Proqr Therapeutics Ii Bv | Stereospecific Linkages in RNA Editing Oligonucleotides |
| WO2020001793A1 (en) | 2018-06-29 | 2020-01-02 | Eberhard-Karls-Universität Tübingen | Artificial nucleic acids for rna editing |
| EP3830259A4 (en) | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
| PE20211402A1 (es) | 2018-10-12 | 2021-08-02 | Univ Beijing | Metodos y composiciones para editar acidos ribonucleicos |
| WO2020092448A1 (en) | 2018-10-29 | 2020-05-07 | Spin Therapeutics, Llc | Compositions and methods for alpha-1-antitrypsin disorders |
| US20200147124A1 (en) * | 2018-11-08 | 2020-05-14 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| CA3127241A1 (en) | 2019-01-22 | 2020-07-30 | Korro Bio, Inc. | Rna-editing oligonucleotides and uses thereof |
| AU2020210900B2 (en) | 2019-01-22 | 2025-04-24 | Korro Bio, Inc. | RNA-editing oligonucleotides and uses thereof |
| CN113573717A (zh) | 2019-01-22 | 2021-10-29 | 科罗生物公司 | Rna编辑的寡核苷酸及其用途 |
| EP3918067A1 (en) | 2019-01-28 | 2021-12-08 | ProQR Therapeutics II B.V. | Rna-editing oligonucleotides for the treatment of usher syndrome |
| GB201901873D0 (en) | 2019-02-11 | 2019-04-03 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for nucleic acid editing |
| US20230174989A1 (en) | 2020-05-15 | 2023-06-08 | Korro Bio, Inc. | Methods and Compositions for the ADAR-Mediated Editing of ABCA4 |
| WO2021243023A1 (en) | 2020-05-28 | 2021-12-02 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of serpina1 |
-
2020
- 2020-01-22 AU AU2020210900A patent/AU2020210900B2/en active Active
- 2020-01-22 EP EP20744578.4A patent/EP3914259A4/en active Pending
- 2020-01-22 WO PCT/US2020/014510 patent/WO2020154342A1/en not_active Ceased
- 2020-01-22 US US16/749,608 patent/US20200385713A1/en not_active Abandoned
- 2020-01-22 TW TW109102639A patent/TW202043469A/zh unknown
- 2020-01-22 KR KR1020217024842A patent/KR20210132022A/ko active Pending
- 2020-01-22 CN CN202080015037.5A patent/CN113453694A/zh active Pending
- 2020-01-22 JP JP2021541718A patent/JP7629404B2/ja active Active
- 2020-01-22 CA CA3126947A patent/CA3126947A1/en active Pending
-
2023
- 2023-05-09 US US18/314,258 patent/US12173285B2/en active Active
-
2024
- 2024-09-13 JP JP2024158942A patent/JP2025003992A/ja active Pending
- 2024-11-08 US US18/941,793 patent/US20250066773A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022518477A5 (cg-RX-API-DMAC10.html) | ||
| JP2022519184A5 (cg-RX-API-DMAC10.html) | ||
| JP2022518731A5 (cg-RX-API-DMAC10.html) | ||
| JP2023536593A5 (cg-RX-API-DMAC10.html) | ||
| JP2022527814A5 (cg-RX-API-DMAC10.html) | ||
| EP4261284A1 (en) | Stable target-editing guide rna to which chemically modified nucleic acid is introduced | |
| JP2022536173A (ja) | シチジンアナログを含むアンチセンスrna編集オリゴヌクレオチド | |
| JP7755837B2 (ja) | オリゴヌクレオチド及び標的rnaの部位特異的編集方法 | |
| US20220127609A1 (en) | Antisense oligonucleotides for nucleic acid editing | |
| EP4555085A1 (en) | Chemically modified oligonucleotides for adar-mediated rna editing | |
| JP2019518772A5 (cg-RX-API-DMAC10.html) | ||
| EP4372091A2 (en) | Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides | |
| WO2024013361A1 (en) | Oligonucleotides for adar-mediated rna editing and use thereof | |
| US20230235329A1 (en) | Antisense oligonucleotides (aso) for efficient and precise rna editing with endogenous adenosine deaminase acting on rna (adar) | |
| JP2024519733A5 (cg-RX-API-DMAC10.html) | ||
| Grein et al. | 3-Deaza-and 7-deazapurines: duplex stability of oligonucleotides containing modified adenine or guanine bases | |
| JP2025541721A (ja) | 化学修飾アンチセンスオリゴヌクレオチド(aso)およびそれを含むrna編集のための組成物 | |
| US20030203356A1 (en) | RNase L activator-antisense complexes | |
| US20250376684A1 (en) | Threose nucleic acid antisense oligonucleotides and methods thereof | |
| JP2024542738A5 (cg-RX-API-DMAC10.html) | ||
| WO2025047679A1 (ja) | リン酸部修飾を導入した安定型標的編集ガイドrna | |
| Beck et al. | A double-headed nucleotide with two cytosines: DNA with condensed information and improved duplex stability | |
| WO2023117738A1 (en) | Threose nucleic acid antisense oligonucleotides and methods thereof | |
| JP2024547071A5 (cg-RX-API-DMAC10.html) | ||
| Mangla et al. | Advances in the synthesis and antisense technology applications of bridged nucleic acid monomers |